{"organizations": [], "uuid": "6f0e5bad194c5a14975a8f4a2db04a1d7f0784a7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180216.html", "section_title": "Archive News &amp; Video for Friday, 16 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/apricus-fda/u-s-fda-declines-to-approve-apricus-erectile-dysfunction-cream-idUSL4N1Q61TA", "country": "US", "domain_rank": 408, "title": "U.S. FDA declines to approve Apricus' erectile dysfunction cream", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.631, "site_type": "news", "published": "2018-02-16T20:10:00.000+02:00", "replies_count": 0, "uuid": "6f0e5bad194c5a14975a8f4a2db04a1d7f0784a7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/apricus-fda/u-s-fda-declines-to-approve-apricus-erectile-dysfunction-cream-idUSL4N1Q61TA", "ord_in_thread": 0, "title": "U.S. FDA declines to approve Apricus' erectile dysfunction cream", "locations": [], "entities": {"persons": [{"name": "savio", "sentiment": "none"}, {"name": "vitaros", "sentiment": "none"}, {"name": "tamara mathias", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "apricus biosciences inc", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 16 (Reuters) - Apricus Biosciences Inc said on Friday the U.S. Food and Drug Administration declined to approve Vitaros, a cream-based treatment for erectile dysfunction, in its present form.\nThe FDA flagged certain safety concerns related to an ingredient in the drug, which was first rejected by the regulator a decade ago. (Reporting by Tamara Mathias in Bengaluru; Editing by Savio Dâ€˜Souza)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-16T20:10:00.000+02:00", "crawled": "2018-02-17T14:26:55.001+02:00", "highlightTitle": ""}